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tine as for comparator. The price sensitivity analysis of comparators was done. The 
reassessment of CEA after price cut of comparators (up to—10%, due to international 
price referencing) has showed the positive results for agomelatine and robustness of 
previous price sensitivity analysis. CONCLUSIONS: The focus of the MoH drug 
policy is on more rational spendings , especially on reference pricing and HTA. There 
are ﬁrst results of these new procedures, where the real impact of the HTA in the 
decision processes is demonstrated. Agomelatin, a new agent in therapy of depression 
fulﬁlled, the necessary legislative conditions including pharmacoeconomic aspects to 
be listed in the positive reimbursement list.
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PREDICTORS AND COSTS OF MDD TREATMENT WITH DULOXETINE 
COMPARED WITH VENLAFAXINE EXTENDED RELEASE
Swindle R1, Ye W2, Robinson RL1, Zhao Y1
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OBJECTIVES: To examine whether non-generic duloxetine and venlafaxine XR are 
essentially interchangeable in patients with major depressive disorder (MDD) or used 
selectively for patients with different treatment histories, costs, demographics, and 
comorbidities. METHODS: Using the US PharMetrics Database, we studied com-
mercially insured individuals aged 18–64 initiating treatment with duloxetine or ven-
lafaxine XR between July 2005 and July 2006, with q1 prior MDD diagnosis and 
continuous enrollment for 12 months prior to initiation date. Initiation was deﬁned 
as the ﬁrst use of either medication preceded by 3 months no prescription for or use 
of the same medication. Chi-square and logistic regression analysis of patients’ demo-
graphics, past-year medication use, and comorbidities were used to assess predictors 
of initiations with duloxetine versus venlafaxine XR. RESULTS: A total of 9641 
patients (73.6% female) initiated treatment with duloxetine and 8514 (71.5% female) 
with venlafaxine XR. Compared to venlafaxine XR patients, duloxetine patients were 
older (45 vs. 42.4 years), had q3 unique prior pain medications (25.5% vs. 15.6%), 
SSRIs (59.5% vs. 52.7%), TCAs (12.6% vs. 7.8%), analgesics (63.1% vs. 51.3%), 
anticonvulsants (30.1% vs. 17.9%), hypnotics (30.2% vs. 22.3%), and had q8 unique 
comorbid medical conditions (38.6% vs. 29.1%) and pain diagnoses (76.3% vs. 
67.8%) (all p-values 0.005). Logistic regression results revealed that 61% of dulox-
etine initiators and 61% of venlafaxine XR initiators were predictable from prior 
patient and treatment factors. The prior 6-month total health care costs were $1731 
higher for future duloxetine patients than for future venlafaxine XR patients, and 
despite higher subsequent pharmacy costs, total health care costs declined for both 
medications after treatment with each drug began. CONCLUSIONS: MDD patients 
treated with duloxetine tended to have a more complex and costly antecedent clinical 
presentation compared with venlafaxine XR-treated patients, suggesting physicians do 
not use the two medications interchangeably and both may have unique roles on 
formularies.
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OBJECTIVES: This retrospective study aimed to explore predictors of duloxetine 
versus other antidepressants for treating patients with major depressive disorder 
(MDD) in the Veterans Affairs (VA) health system. Duloxetine was not on the VA 
national drug formulary. METHODS: The electronic medical records from October 
2004 to October 2008 were extracted from the VA Veterans Integrated Service 
Network 16 data warehouse. All patients were treated with either duloxetine mono-
therapy (duloxetine) or other antidepressants (non-duloxetine) over the study period, 
with the ﬁrst dispense date of the index agent as the index date. All patients must 
have at least 1 prior MDD diagnosis (ICD-9-CM: 296.2 or 296.3), but no prior dia-
betes (ICD-9-CM: 250.xx) or bipolar disorder (ICD-9-CM: 296.4x-296.8x) diagnosis. 
Logistic regression was used to examine the predictors of treatment of duloxetine 
versus other antidepressants, controlling for demographics, comorbidities, prior 
opioid use, and pain level in the 12 months pre-index period. RESULTS: The logistic 
regression sample included 12,077 patients (duloxetine: n  448; non-duloxetine: n  
11,629). Patients who were female (odds ratio [OR]  3.15, 95% Conﬁdence Interval 
[CI]: 2.48–4.00), white (OR  1.48, CI: 1.15–1.91), with non-VA insurance (OR  
1.69, CI: 1.24–2.31), or prior emergency department (ED) visit (OR  1.64, CI: 
1.21–2.22) were more likely to use duloxetine. Patients comorbid with dyslipidemia, 
hypertension, or substance abuse were 1.60 (CI: 2.08–3.25), 0.35 (CI: 1.09–1.68), and 
0.41 (CI: 1.14–1.75) times more likely to use duloxetine. Prior short-acting and long-
acting opioid users were 3.32 (CI: 2.60–4.23) and 8.98 (CI: 6.95–11.60) times as likely 
to use duloxetine as those with no prior opioid use, respectively. Patients with self-
reported moderate or severe pain were 1.43 (CI: 1.07–1.90) or 1.50 (CI: 1.16–1.92) 
times as likely to use duloxetine as those with no pain. CONCLUSIONS: The VA 
patients who were treated with duloxetine appeared to have more ED visits, more 
comorbid conditions, prior substance abuse or opioid use, and higher pain levels.
NEUROLOGICAL DISORDERS – Clinical Outcomes Studies
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MULTIPLE SCLEROSIS AND THE NUMBER AND SEVERITY OF RELAPSES
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OBJECTIVES: To determine if patients are adherent with interferons used to treat 
patients with Multiple Sclerosis (MS), the optimal adherence rate to maximize clinical 
outcomes, and the impact of adherence on the number and severity of relapses. 
METHODS: A retrospective cohort study design was used. Pharmacy and medical 
claims data were extracted for 2006–2008. Adherence was measured using two stan-
dard methods for Medication Possession Ratio (MPR), one that incorporates persis-
tence and one that does not. Threshold analyses were run to determine an optimal 
adherence rate to minimize relapses. Patients were considered adherent if they met a 
predeﬁned standard cut-off point and reanalyzed with the newly determined cut point. 
The number and severity of relapses were measured for each patient year, with 2008 
being the critical outcomes point. A series of regression models were used to assess 
the impact of adherence on the number and severity of relapses. RESULTS: A total 
of 3590 patients were included in the study. Based on the method, the average MPR 
varied between 77.6% and 89.8%. The threshold analysis determined that the optimal 
adherence rate is around 85%. Patients receiving interferon through a specialty phar-
macy are more adherent than those who did not. Patients who were classiﬁed as 
adherent through 2007 had a signiﬁcantly lower risk of relapse in 2008. Patients who 
were adherent also had a signiﬁcantly lower risk of severe relapse than those who 
were non-adherent. Complete MPRs, adherence rates, individual year descriptives, and 
inferential statistics will be included in the presentation. CONCLUSIONS: Patients 
with MS are generally adherent with their interferon therapy, although opportunities 
for improvement exist. Patients who receive special pharmacy services are more adher-
ent than those who receive standard retail services. The effect of adherence on the 
number and severity of relapses demonstrated the positive impact of interferons for 
MS treatment.
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OBJECTIVES: The aim of this study was to evaluate the efﬁcacy for ﬁve FDA 
approved drugs for Alzheimer’s disease. METHODS: MEDLINE and the International 
Pharmaceutical Abstracts databases were searched for studies addressing functional 
outcomes with Alzheimer’s disease. The primary outcome was cognitive efﬁcacy and 
must have been measured on a validated scale. To report one consistent scale value, 
values were transformed into z-scores to obtain a dichotomized output, categorized 
as either improvement or a lack therof in treatment. Odds ratios were calculated for 
success for each drug treatment. Winbugs version 1.4 statistical software was used to 
conduct a mixed treatment comparisons Bayesian analysis along with a sub-analysis 
to examine whether or not the cognitive measurement scale used in the studies effects 
the ranking of drug treatments. RESULTS: The mixed treatment comparisons results 
showed that galantamine OR  2.518E7, 95%CRI: 447,300–7.034E9 was highly 
favored above all other Alzheimer’s treatments, followed by donepezil OR  1557, 
95%CRI: 315.4–8341, tacrine OR  212.8, 95%CRI: 28.47–1604, rivastigmine OR 
 23.57, 95%CRI: 5.397–104.8, memantine OR  3.775, 95%CRI: 0.639–23.09 
compared to placebo. The sub-analysis also showed that galantamine OR  2.832E7, 
95%CRI: 483900–2.326E10 as highly favored, but yielded slightly different results 
with tacrine OR  1434, 95%CRI: 148.2–15830 ahead of donepezil OR  471.2, 
95%CRI: 83.48–2935 in ranking, followed by rivastigmine OR  19.54, 95%CRI: 
4.781–83.19 and memantine OR  2.836, 95%CRI: 0.2196–37.96. This analysis 
removed the eight studies that did not use the ADAS-Cog measurement scale, suggest-
ing that the selection of the cognitive measurement scale changes the ranking of drug 
treatments. Odds ratios for galantamine were high due to the favorable response (q95) 
for the drug. The severity of Alzheimer’s disease was not taken into account in this 
study. CONCLUSIONS: The consistency between drugs in terms of cognitive efﬁcacy 
is present in all ﬁve drugs; all demonstrating effectiveness over placebo. Future 
research in this area is needed, including clinical studies comparing the agents 
directly.
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OBJECTIVES: The aim of this meta-analysis was to evaluate the efﬁcacy and tolerabil-
ity of Natalizumab in relapsing multiple sclerosis (MS). METHODS: “Mean change 
in Expanded Disability Status Scale (EDDS)”, “number of patients with at least one 
relapse”, and “number of patients with at least one new gadolinium (Gd)-enhancing 
lesion” were the key outcomes of interest for assessment of efﬁcacy. “Any adverse 
events”, “serious adverse events”, “death”, and “withdrawal because of adverse 
events” were the key outcomes for tolerability. RESULTS: Amongst existing trials, 
four randomized placebo controlled clinical trials met our criteria and were included. 
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Pooled Relative Risk for at least one relapse in four trials including all doses was 0.7, 
a non-signiﬁcant RR (95% CI: 0.42–1.17, P  0. 17). Summary RR for at least one 
relapse in two trials in which doses of 3 mg/kg or 6 mg/kg or 300 mg every 4 weeks 
were administered gave a values of 0.5 as a signiﬁcant RR (95% CI: 0.42–0.61, P  
0.0001). The summary RR for at least one new Gd-enhancing lesion was 0.22, a 
non-signiﬁcant RR (95% CI: 0.05–1.01, P  0.051). Three deaths were reported in 
natalizumab group. Comparing adverse events between natalizumab and placebo 
yielded a non signiﬁcant RR of 0.99 (95% CI: 0.96–1.01, P  0.34) for any adverse 
events (n  3), and a signiﬁcant RR of 0.39 (95% CI: 0.29–0.52, P  0.0001) for 
serious adverse events (n  2). A summary RR for withdrawal due to adverse events 
by natalizumab vs. placebo therapy between two trials was 1.43, a non-signiﬁcant RR 
(95% CI: 0.68–3.02, P  0.35). CONCLUSIONS: It seems that using 3 mg/kg or 
6 mg/kg every four weeks is the best experienced method of administration of natali-
zumab for preventing relapse and occurrence of new Gd-enhancing. Further clinical 
trials are still needed.
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OBJECTIVES: Multiple Sclerosis (MS) is a chronic, recurrent, inﬂammatory disease 
with unrelenting attacks from the immune system. It is the major cause of non-
 traumatic disability in young adults. Iran, contrary to the other countries in Middle-
east, is considered to have a high prevalence of MS that mentioned as the National 
disaster in Iran. While much is known about the MS in the world, there is a paucity 
of the feature of MS in Iran. METHODS: In a 6-month cross-sectional study 248 MS 
patients were studied in Iran. Data was collected by employing a 32- item self-admin-
istered questionnaire. Parametric, nonparametric tests and descriptive statistics analy-
sis were applied (p value 0.05). RESULTS: The prevalence and incidence was 
estimated to be 25/100000 and 2.5/100,000, respectively. The patients were diagnosed 
in 2001 onward were more frequently than the patients in1981–1990(40:1). The mean 
age 31.9 o 8.7, the mean onset age 26.3(26.3 o 8:1) and the mean duration of illness 
were 5.6 o 5.3 years. A family history of ms was reported in 11%. The sex ratio was 
3:1(female : male). CONCLUSIONS: In contrast to reports from Caucasians , MS 
Iranian population signiﬁcantly differ with respect to the age, onset age, disease dura-
tion, family history and sex ratio. This might reﬂect the different in some environmen-
tal-genetic factors and life style as well, in this population. Some of our ﬁnding were 
comparable to the so-called “western type” of MS such as : BMI, birth season and 
education stand.
NEUROLOGICAL DISORDERS – Cost Studies
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BUDGET IMPACT ANALYSIS IN THE TREATMENT OF MAJOR 
DEPRESSIVE DISORDER IN VARIOUS ITALIAN REGIONS: THE ROLE OF 
VENLAFAXINE
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Economiche, Milano, Milano, Italy
OBJECTIVES: Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) 
approved for the treatment of major depressive disorder (MDD). Following patent 
expiration, venlafaxine is available as generic at a reduced price. We evaluated the 
overall savings to the National Health System (NHS) following venlafaxine’s price 
reduction. METHODS: A simulation model was constructed in Microsoft Excel to 
carry out a Budget Impact Analysis. Three scenarios were hypothesized: the ﬁrst simu-
lation evaluated the potential savings to the NHS following venlafaxine’s price reduc-
tion. The second and third simulations assessed additional potential savings to the 
NHS supposing an increase in the market share of venlafaxine by substitution of dif-
ferent proportions of other branded products namely duloxetine and escitalopram. 
Costs were obtained from IMS Health, efﬁcacy data were derived from the available 
literature. RESULTS: Mean annual treatment cost with venlafaxine decreased from 
a567 to a284 resulting in overall savings to the NHS of more than a44 million per 
year. Treatment switching from escitalopram and/or duloxetine to venlafaxine was 
always a dominant strategy and resulted in a higher number of patients treated more 
efﬁcaciously since venlafaxine performs better in terms of remission and is less expen-
sive. Sensitivity analyses on effectiveness (response) and cost variables conﬁrmed our 
results. CONCLUSIONS: This analysis suggests that extended use of generic venla-
faxine is likely to lead to overall cost savings to the NHS due to its cost-effectiveness 
proﬁle compared with other antidepressants such as duloxetine and escitalopram.
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OBJECTIVES: Previous research identiﬁed hypnotic-users to have a greater risk of 
falls and fractures vs. controls. The objective of this study was to determine the 
economic burden of falls and fractures to managed care among hypnotic users. 
METHODS: A retrospective study was designed using data from a national managed 
care commercial claims database. First time hypnotic-users were identiﬁed using 
pharmacy claims and matched to two controls on gender, region, payer, and age. 
Subjects were followed for 12-months post index-date to capture events and costs of 
falls and fractures identiﬁed using speciﬁc ICD-9-CM and E-codes. Multivariate 
regression models were used to estimate the incremental burden of falls or fractures 
at a per-hypnotic user per year (PHUPY) for a hypothetical managed care plan of 1 
million membership with hypnotic-use rate of 4.5% and stratiﬁed by age-categories: 
young-adults (18–44 yrs), middle-age (45–64 yrs) and elderly (65 yrs). RESULTS: A 
total of 40,549 hypnotic-users and 81,098 controls met the inclusion criteria. Both 
groups were demographically similar (p  0.05) at baseline. Hypnotic-users had higher 
Charlson comorbid index scores (1.07 vs. 0.60, p  0.001) and proportion of balance 
disorders (3.33% vs. 2.18%, p  0.001) compared to controls. For those who had an 
event, the total annual mean direct costs of managing falls and fractures was $2,559 
(95%CI: 2117–3001), and $3294 (95%CI: 2916–3673), respectively, with costs lin-
early increasing with age. Based on hypnotic-use rate of 4.5% and age distribution, 
total hypnotic-users in the hypothetical plan were estimated to be 33,750. Falls/frac-
ture related PHUPY translated into $50 (Range: 24–82), $63 (Range: 39–92), and 
$245 (Range: 28–615) for young, middle-age and elderly hypnotic users. Overall 
burden due to falls/fractures as a consequence of hypnotic use to managed care was 
estimated to be $2,092,500 (Range: 1,451,250–2,801,250) CONCLUSIONS: The 
unintended consequence (i.e. managing falls/fractures) of current hypnotic use may be 
burdensome to a managed care plan.
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OBJECTIVES: Sugammadex (SGX) is a modiﬁed gamma-cyclodextrin that bonds with 
rocuronium and vecuronium, leading to reversal of the neuromuscular blockade. The 
objective of this study was to evaluate the budget impact and the cost-effectiveness of 
SGX in the routine reversal of patients with neuromuscular block (NMB) from the 
Spanish National Health System perspective. METHODS: A decision-analytic (DAM) 
and a budget impact model (BIM) was developed to assess the mean treatment costs 
per patient (a2009), life-years gained (LYG), and incremental cost per LYG of SGX, 
the spontaneous reversal and neostigmine/atropine in the reversal of patients with 
NMB. The DAM simulates the probability of experiencing an adverse effect and the 
direct costs produced by each treatment alternative. The BIM accounts for the time 
that SGX could save in the operating room (OR), shortening the time to extubation, 
thereby accelerating the movement of patients in and out of the OR. Clinical data was 
obtained from the clinical trial performed with SGX, the SmPC of each drug and form 
secondary sources. Costs were obtained for Soikos database. RESULTS: In the routine 
reversal of patients, ROCSGX is associated with higher costs than the spontaneous 
reversal or neostigmine/atropine but also with higher LYG. The cost-effectiveness 
range of SGX vs. neostigmine/atropine varies between a13,26 and 4,976 per LYG, 
and vs. spontaneous reversal between a6,880 and 17,657 per LYG. In the BIM, SGX 
could save between 108 and 171 minutes of OR, that would mean that 1 or 2 more 
surgeries could be performed, and a total budget saved between a1400 and 2000 per 
OR per day. CONCLUSIONS: Under the established assumptions, SGX would be a 
cost-effective alternative for the routine reversal of patients with NMB and could be 
a cost-saving strategy due to the increase of the turn over of the OR.
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COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF 
SUBCUTANEOUS INTERFERON BETA-1A FOR RELAPSING-REMITTING 
MULTIPLE SCLEROSIS IN SPAIN
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OBJECTIVES: Relapsing-remitting multiple sclerosis (RRMS) is the most common 
form of multiple sclerosis. Beta interferons have been shown to reduce relapse rates 
by a third. The aim of this study is assessing the value of subcutaneous interferon 
beta-1a when compared to other available disease modifying drugs for RRMS patients 
in Spain. METHODS: Pharmacoeconomic model based on subcutaneous interferon 
beta-1a clinical trials efﬁcacy data (relapses and progression of disability both on the 
medium and long run) and local expert panel. This analysis was undergone from the 
Spanish National Health System (SNHS) perspective, included only direct medical 
costs and employed an annual discount rate of 3% on both costs and health outcomes. 
The model provided estimations of cost per avoided relapse and cost per avoided 
progression, as well as probabilistic sensitivity analysis with 1000 Monte Carlo simu-
lations. Budget impact analysis was also undergone to forecast the implications of 
subcutaneous interferon beta-1a increased market share in a 4-year horizon. RESULTS: 
Subcutaneous interferon beta-1a and natalizumab result in the lowest MS relapse rates 
with an estimated cost per avoided relapse of a28,847, a29,918, a36,299, a42,027 
and a55,379 when subcutaneous interferon beta-1a, interferon beta-1b, glatiramer 
acetate, natalizumab and intramuscular interferon-1a are employed. Cost per avoided 
